September 04, 2019 08:00 AM Eastern Daylight Time
SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland–(BUSINESS WIRE)–Since it was conceived, Versant Ventures has provided enabling support for the design and launch of an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Today Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with $225 million in committed capital. The fund was oversubscribed, and it was raised from a broad range of institutional investors including public pensions, university endowments, foundations, leading academic health systems, family offices and fund-of-funds.
Vensana Capital seeks to partner with innovative medical technology companies in their clinical development and commercial stages. Vensana’s team has a proven track record of identifying, financing, and building medtech companies to establish new standards of care in their field. Co-founders Kirk Nielsen and Justin Klein, M.D., J.D., were previously leading medtech-focused investors at Versant and New Enterprise Associates, respectively READ MORE AT BUSINESS WIRE….
